---
schema_version: "secwatch.filing_event.v1"
accession: "0001829126-25-005008"
form_type: "8-K"
ticker: "NTHI"
cik: "0001979414"
company_name: "NEONC TECHNOLOGIES HOLDINGS, INC."
filed_at: "2025-07-10T23:59:59+00:00"
generated_at: "2026-05-18T08:47:51.005066+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# NeOnc signs $50M non-binding term sheet with Quazar for UAE clinical platform expansion

## Summary
- $50M equity investment at $25/share from Quazar Investment; board approved June 30, 2025.
- Formation of NuroMENA Holdings and NuroCure in UAE to run clinical trials for NEO100 and NEO212.
- 70% of funds to buy NTHI common stock at $25/share; 30% for clinical trials and infrastructure.
- Conditions include sub-license from USC Stevens Center, offering docs, and two-year plan within 120 days.
- Partnership leverages Cleveland Clinic Abu Dhabi for trials under US FDA protocols.

## SEC filing metadata
- accession: 0001829126-25-005008
- form_type: 8-K
- ticker: NTHI
- cik: 0001979414
- company_name: NEONC TECHNOLOGIES HOLDINGS, INC.
- filed_at: 2025-07-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1979414/000182912625005008/0001829126-25-005008-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1979414/000182912625005008/neonctechnologies_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001829126-25-005008
- JSON: https://secwatch.observer/filing/0001829126-25-005008.json
- Plain text: https://secwatch.observer/filing/0001829126-25-005008.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.